5,6-Dihydroxy-2-naphthoic acid β-phenylethyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5,6-Dihydroxy-2-naphthoic acid β-phenylethyl ester
• 英文别名: Phenethyl 5,6-dihydroxynaphthalene-2-carboxylate；2-phenylethyl 5,6-dihydroxynaphthalene-2-carboxylate
• 化学式: C₁₉H₁₆O₄
• 分子量: 308.334
• InChiKey: OFPFJSWYCBDRHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5,6-dimethoxy-2-naphthalenecarboxylic acid 在 氩 、 5,6-dihydroxy-2-naphtohoic 、 苯乙醇 、 silica gel 作用下， 以 吡啶 为溶剂， 反应 0.67h， 以to provide product 67H-52-A as a white solid (1200 mg, 36% yield overall)的产率得到5,6-Dihydroxy-2-naphthoic acid β-phenylethyl ester
  参考文献：
  名称：

  Method for the treatment of hyperproliferative epithelial skin diseases

  摘要：

  本发明涉及一种通过局部给药治疗过度增生的上皮病变的方法。该方法可以防止这些异常细胞的生长并积极地交联这些细胞，从而杀死这些细胞。本发明在控制和预防过度增生的上皮疾病方面非常有用，例如HPV感染的细胞病变、日光性角化病、黑色素瘤以及恶性和前恶性癌症。

  公开号：

  US05610185A1

文献信息

• Method for the treatment of hyperproliferative epithelial skin diseases
  申请人：The United States of America as represented by the Department of Health

  公开号：US05610185A1

  公开（公告）日：1997-03-11

  The present invention relates to a method of treating hyperproliferative epithelial lesions by topical administration. The method prevents growth and actively cross-links these aberrant cells, thereby killing the cells. The present invention is useful in control and prevention of hyperproliferative epithelial disorders, such as HPV-infected cell lesions, actinic keratosis, melanomas, and malignant and pre-malignant carcinomas.

  本发明涉及一种通过局部给药治疗过度增殖的上皮病变的方法。该方法可以防止细胞的生长并积极地交联这些异常细胞，从而杀死这些细胞。本发明对于控制和预防过度增殖的上皮疾病非常有用，例如HPV感染细胞病变、日光性角化症、黑色素瘤以及恶性和癌前病变的癌症。
• A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS
  申请人：THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：EP0809493A1

  公开（公告）日：1997-12-03
• METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS
  申请人：CONRAD CHARLES

  公开号：US20080167277A1

  公开（公告）日：2008-07-10

  Methods of treating skin diseases such as plaque psoriasis and inverse psoriasis include topical application of one or a combination of caffeic acid phenethyl ester, caffeic acid benzyl ester, and analogs thereof as an active agent. A pharmaceutical composition containing the active agent may further include a cell differentiating agent such as a retinoid, and/or vitamin D or analogs thereof. The method enables treatment of a lesion with active agent dosages of ten percent by weight, for example.
• US5610185A
  申请人：——

  公开号：US5610185A

  公开（公告）日：1997-03-11
• [EN] A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS<br/>[FR] PROCEDE POUR TRAITER LES LESIONS EPITHELIALES HYPERPROLIFERATIVES DE LA PEAU PAR APPLICATION TOPIQUE DE COMPOSES DE RETICULATION DE PROTEINES AROMATIQUES HYDROXYLES
  申请人：THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：WO1996025159A1

  公开（公告）日：1996-08-22

  (EN) The present invention relates to a method of treating hyperproliferative epithelial lesions by topical administration. The method prevents growth and actively cross-links these aberrant cells, thereby killing the cells. The present invention is useful in control and prevention of hyperproliferative epithelial disorders, such as HPV-infected cell lesions, actinic keratosis, melanomas, and malignant and pre-malignant carcinomas.(FR) Cette invention se rapporte à un procédé pour traiter les lésions épithéliales hyperprolifératives de la peau par administration topique. Ce procédé empêche la croissance et entraîne la réticulation active de ces cellules aberrantes, afin de les détruire. Cette invention permet de combattre et prévenir les troubles épithéliaux hyperprolifératifs, telles que les lésions cellulaires infectées par HPV, la kératose actinique, les mélanomes et les carcinomes malins et prémalins.